Tag Archive for: BioPharma

Poolbeg Pharma – POLB 001 LPS Challenge Trial Data to be Presented at IUIS

/in

POLB 001 – a potential blockbuster immunomodulator 16 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted for presentation at the 18th International […]

Read more

Poolbeg Pharma plc – Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma

/in

Poolbeg team boosted by highly experienced executives with track record of success 9 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces the appointment of key former executives of Amryt Pharma plc (‘Amryt’) to its leadership team. Read more…

Read more

Poolbeg Pharma plc – POLB 001 Data to be Presented at American Society of Hematology Annual Meeting

/in

Potential to address cancer treatment related Cytokine Release Syndrome 3 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that an abstract detailing POLB 001’s promise as a potential treatment for Cytokine Release Syndrome associated with cancer immunotherapies has been accepted for presentation at 65th American […]

Read more

Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company on its Oral Delivery Platform

/in

Strategic collaboration focussed on the development of an optimised drug for a metabolic condition using Poolbeg’s licensed oral delivery technology Collaboration may expand to a full licensing agreement 17 October 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has signed a […]

Read more

Poolbeg Pharma plc – Positive Conclusion Reached in Immunomodulator I Patent Opposition

/in

29 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that further to its announcement on 19 September 2023, the oral opposition hearing scheduled by the European Patent Office (‘EPO’) relating to the challenge to the Company’s European patent (Immunomodulator I), has been cancelled. This favourably […]

Read more